| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 754 | 831 | 871 | 823 | 819 | 1,299 | 795 | 803 | 707 | 888 | 834 | 785 | 764 | 964 | 838 | 2,132 | 776 | 939 | 826 | 826 | 815 | 985 | 833 | 962 | 850 | 1,050 | 985 | 1,015 | 849 | 1,016 | 1,091 |
| Expenses | 608 | 663 | 688 | 588 | 623 | 688 | 1,408 | 602 | 535 | 739 | 611 | 707 | 586 | 678 | 636 | 634 | 596 | 660 | 585 | 618 | 618 | 668 | 751 | 673 | 584 | 689 | 658 | 641 | 554 | 644 | 670 |
| EBITDA | 145 | 168 | 183 | 236 | 196 | 611 | -613 | 201 | 172 | 150 | 223 | 78 | 178 | 286 | 202 | 1,497 | 180 | 279 | 241 | 208 | 198 | 318 | 83 | 290 | 266 | 361 | 327 | 374 | 295 | 372 | 421 |
| Operating Profit % | 17 % | 19 % | 17 % | 22 % | 21 % | 22 % | -81 % | 22 % | 18 % | 16 % | 23 % | 5 % | 18 % | 27 % | 22 % | 22 % | 20 % | 28 % | 27 % | 22 % | 19 % | 30 % | 7 % | 28 % | 28 % | 32 % | 31 % | 34 % | 31 % | 34 % | 36 % |
| Depreciation | 11 | 12 | 12 | 14 | 19 | 23 | 18 | 23 | 22 | 22 | 18 | 18 | 18 | 17 | 18 | 15 | 16 | 16 | 16 | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Profit Before Tax | 134 | 157 | 171 | 222 | 176 | 587 | -634 | 177 | 149 | 127 | 204 | 60 | 160 | 268 | 184 | 1,482 | 163 | 262 | 224 | 190 | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 | 400 |
| Tax | 50 | 56 | 57 | 75 | 63 | 85 | 27 | 39 | 38 | 51 | 48 | 45 | 39 | 64 | 34 | 263 | 44 | 69 | 60 | 57 | 49 | 82 | 20 | 76 | 67 | 91 | 78 | 96 | 74 | 97 | 104 |
| Net Profit | 84 | 101 | 114 | 147 | 114 | 503 | -661 | 138 | 111 | 77 | 157 | 14 | 121 | 204 | 150 | 1,219 | 119 | 193 | 165 | 133 | 132 | 218 | 46 | 195 | 182 | 253 | 230 | 263 | 205 | 258 | 296 |
| EPS in ₹ | 9.93 | 5.95 | 6.71 | 8.67 | 6.70 | 29.68 | -39.03 | 8.15 | 6.54 | 4.51 | 10.26 | 0.85 | 7.14 | 12.06 | 8.87 | 71.96 | 7.04 | 11.42 | 9.71 | 7.41 | 7.04 | 12.84 | 9.89 | 11.37 | 10.76 | 14.67 | 13.57 | 15.52 | 12.10 | 15.07 | 16.54 |
GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals
2,472.00
-22.60
(-0.91%)
Market Cap
41,877.17 Cr
PE Ratio
41.34
Volume
56,508.00
Day High - Low
2,509.60 - 2,459.80
52W High-Low
3,515.70 - 2,217.60
Key Fundamentals
Market Cap
41,877.17 Cr
EPS
54.76
PE Ratio
41.34
PB Ratio
24.72
Book Value
100.80
EBITDA
1,323.30
Dividend Yield
2.17 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
47.54
Debt to Equity
0.01
Analyst Rating and Forecast
- By Refinitiv from4 analysts
Actual
Company News
View All News
GlaxoSmithKline Pharmaceuticals Limited announces board meeting on May 13, 2026, to approve audited financial results for year ended March 31, 2026, and consider dividend recommendation.
GlaxoSmithKline Pharmaceuticals Limited announces the appointment of Mr. Vinay Subramanian as Commercial Head – Oncology to its leadership team, effective 20th April 2026, bringing over 24 years of pharmaceutical industry experience.
GlaxoSmithKline Pharmaceuticals Limited has disclosed four authorized personnel including Managing Director Bhushan Akshikar and CFO Ronojit Biswas for determining materiality of events under SEBI Regulation 30(5). The disclosure was made to BSE and NSE on 21 April 2026.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,620.40 | #1 3,88,788.24 | 36.80 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 33.27 | |
6,361.50 | 1,68,877.84 | 68.31 | 9,712.00 | 18.67 | 2,191 | -1.02 | 63.24 | |
4,117.20 | 1,39,344.76 | 61.76 | 11,539.40 | 6.99 | 1,911 | 26.24 | 45.65 | |
1,317.10 | 1,09,930.83 | 20.15 | 33,741.20 | 16.73 | 5,725 | -15.28 | 61.94 | |
2,296.10 | 1,04,941.69 | 22.91 | 22,909.50 | 13.74 | 3,306 | #1 37.44 | 47.90 | |
1,295.00 | 1,04,607.60 | 23.27 | 28,409.50 | 7.12 | 5,291 | -57.18 | 60.61 | |
2,267.40 | 93,599.42 | 52.47 | 12,744.20 | #1 20.90 | 2,007 | 7.65 | 67.86 | |
927.40 | 93,318.14 | #1 18.96 | 23,511.00 | 18.55 | 4,615 | -0.32 | 55.15 | |
1,413.80 | 82,113.73 | 23.93 | 32,345.60 | 9.43 | 3,484 | 7.59 | 66.95 | |
2,299.50 | 64,892.08 | 61.93 | 13,435.50 | 6.18 | 1,047 | 15.86 | 63.32 |
Growth Rate
Revenue Growth
8.91 %
Net Income Growth
57.22 %
Cash Flow Change
121.62 %
ROE
43.24 %
ROCE
42.20 %
EBITDA Margin (Avg.)
17.79 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 3,216 | 3,055 | 3,004 | 3,948 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 |
| Fixed Assets | 123 | 210 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 |
| Current Assets | 2,587 | 2,174 | 1,674 | 2,186 | 2,010 | 1,775 | 2,203 | 3,708 | 2,494 | 2,798 | 3,410 |
| Capital Work in Progress | 115 | 268 | 606 | 923 | 1,003 | 120 | 13 | 31 | 20 | 14 | 14 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 |
| Other Assets | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 |
| Total Equity & Liabilities | 3,216 | 3,055 | 3,004 | 3,948 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 |
| Current Liabilities | 1,107 | 579 | 720 | 1,600 | 1,454 | 1,024 | 1,355 | 1,698 | 1,326 | 1,525 | 1,905 |
| Non Current Liabilities | 280 | 292 | 277 | 290 | 317 | 291 | 282 | 272 | 259 | 254 | 252 |
| Total Equity | 1,829 | 2,183 | 2,007 | 2,057 | 2,140 | 1,821 | 1,478 | 2,663 | 1,741 | 1,778 | 1,951 |
| Reserve & Surplus | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 |
| Share Capital | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 21 | -0 | 24 | 62 | -102 | 6 | 300 | -119 | -251 | 29 | 475 |
| Investing Activities | 180 | 499 | 301 | -104 | -153 | -57 | 418 | -406 | 808 | 9 | -46 |
| Operating Activities | 338 | 139 | 234 | 473 | 410 | 491 | 578 | 811 | 484 | 582 | 1,290 |
| Financing Activities | -497 | -638 | -511 | -307 | -358 | -428 | -696 | -524 | -1,543 | -562 | -769 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 3.48 % | 4.02 % | 4.36 % | 4.50 % | 4.52 % | 4.89 % | 4.80 % | 4.64 % | 4.62 % |
| DIIs | 5.31 % | 5.51 % | 5.50 % | 5.61 % | 5.61 % | 4.08 % | 10.45 % | 10.28 % | 10.30 % | 10.23 % | 10.01 % | 8.53 % | 7.90 % | 7.50 % | 7.34 % | 7.30 % | 7.79 % | 7.70 % | 7.75 % | 7.70 % | 7.68 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 11.02 % | 10.86 % | 10.83 % | 10.67 % | 10.41 % | 10.41 % | 10.40 % | 10.56 % | 10.54 % | 10.57 % | 10.62 % | 11.08 % | 11.27 % | 11.15 % | 10.97 % | 10.96 % | 10.60 % | 10.32 % | 10.34 % | 10.36 % | 10.35 % |
| Others | 8.67 % | 8.62 % | 8.67 % | 8.73 % | 8.98 % | 10.51 % | 4.15 % | 4.16 % | 4.16 % | 4.20 % | 4.37 % | 5.38 % | 2.35 % | 2.33 % | 2.33 % | 2.23 % | 2.09 % | 2.09 % | 2.11 % | 2.30 % | 2.35 % |
| No of Share Holders | 1,19,951 | 1,20,476 | 1,21,445 | 1,23,480 | 1,10,141 | 1,12,964 | 1,16,651 | 1,20,127 | 1,20,415 | 1,19,032 | 1,15,266 | 1,14,663 | 1,18,994 | 1,18,515 | 1,19,228 | 1,19,625 | 1,21,885 | 1,23,629 | 1,22,904 | 1,22,460 | 1,21,763 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 30 | 35 | 20 | 40 | 30 | 90 | 32 | 32 | 54 | 0.00 |
| Dividend Yield (%) | 2.87 | 2.7 | 1.59 | 2.78 | 1.8 | 7.05 | 1.64 | 1.11 | 2.37 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Sept 2018 |  Bonus | 1:1 | 11 Sept 2018 | 1,726.60 | 1,724.70 |
| 20 Jul 2021 |  Dividend | ₹ 30.00 /share | 19 Jul 2021 | 1,518.15 | 1,607.55 |
| 08 Jul 2022 | Dividend | ₹ 30.00 /share | 07 Jul 2022 | 1,493.30 | 1,505.90 |
| 08 Jul 2022 | Dividend | ₹ 60.00 /share | 07 Jul 2022 | 1,493.30 | 1,505.90 |
| 26 Jul 2022 |  Annual General Meeting | NA | 26 Jul 2022 | 1,493.30 | 1,493.85 |
| 30 Jun 2023 | Dividend | ₹ 32.00 /share | 30 Jun 2023 | 1,289.55 | 1,438.20 |
| 31 May 2024 | Dividend | ₹ 32.00 /share | 31 May 2024 | 2,023.85 | 2,593.00 |
| 28 Jun 2024 | Annual General Meeting | NA | 28 Jun 2024 | 2,023.85 | 2,677.55 |
| 29 Oct 2024 |  Quarterly Result Announcement | NA | 29 Oct 2024 | 2,630.85 | 2,644.65 |
| 07 Nov 2024 | Dividend | ₹ 12.00 /share | 07 Nov 2024 | 2,644.65 | 2,632.20 |
| 14 Feb 2025 | Quarterly Result Announcement | NA | 14 Feb 2025 | 2,077.20 | 1,998.80 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 2,928.60 | 2,721.25 |
| 30 May 2025 | Dividend | ₹ 42.00 /share | 30 May 2025 | 2,721.25 | 3,263.40 |
| 27 Jun 2025 | Annual General Meeting | NA | 27 Jun 2025 | 2,721.25 | 3,301.90 |
| 01 Aug 2025 | Quarterly Result Announcement | NA | 01 Aug 2025 | 3,262.85 | 3,158.15 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 2,758.10 | 2,661.50 |
| 09 Feb 2026 | Quarterly Result Announcement | NA | 09 Feb 2026 | 2,457.05 | 2,484.00 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
3 days ago
3 days agoBoard Meeting Intimation for Audited Financial Results (Standalone & Consolidated) For The Year Ended 31St March 2026 And Dividend If Any
3 days ago
3 days agoDisclosure Under Regulation 30(5) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 20154 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Change in Management4 days ago
4 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2026
Apr 09, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportApr 08, 2026
Apr 08, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotApr 08, 2026
Apr 08, 2026Disclosure Under Regulation 30Mar 31, 2026
Mar 31, 2026Closure of Trading WindowMar 25, 2026
Mar 25, 2026Disclosure Under Regulation 30Mar 24, 2026
Mar 24, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMar 16, 2026
Mar 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 11, 2026
Mar 11, 2026Postal Ballot NoticeMar 07, 2026
Mar 07, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotMar 07, 2026
Mar 07, 2026Disclosure Under Regulations 30Mar 07, 2026
Mar 07, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMar 02, 2026
Mar 02, 2026Board Meeting Outcome for Outcome Of Board MeetingMar 02, 2026
Mar 02, 2026Disclosure Under Regulations 30Feb 28, 2026
Feb 28, 2026Disclosure Under Regulation 30Feb 23, 2026
Feb 23, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 16, 2026
Feb 16, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 11, 2026
Feb 11, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 10, 2026
Feb 10, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 09, 2026
Feb 09, 2026Financial Results For Quarter & Nine Months December 2025Feb 09, 2026
Feb 09, 2026Board Meeting Outcome for Outcome Of MeetingFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2026
Feb 03, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2026
Jan 08, 2026Board Meeting Intimation for Un-Audited Financial Results For The Third Quarter & Nine Months Ended 31St December 2025.Jan 06, 2026
Jan 06, 2026Disclosure Under Regulation 30Jan 01, 2026
Jan 01, 2026Disclosure Under Regulation 30Dec 31, 2025
Dec 31, 2025Volume Movement LetterDec 31, 2025
Dec 31, 2025Clarification sought from GlaxoSmithKline Pharmaceuticals LtdDec 31, 2025
Dec 31, 2025Closure of Trading WindowDec 23, 2025
Dec 23, 2025Disclosure Under Regulation 30Dec 22, 2025
Dec 22, 2025Disclosure Under Regulation 30Dec 18, 2025
Dec 18, 2025Disclosure Under Regulation 30Dec 12, 2025
Dec 12, 2025Disclosure Under Regulation 30Nov 19, 2025
Nov 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 10, 2025
Nov 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 10, 2025
Nov 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-AcquisitionNov 06, 2025
Nov 06, 2025Results Ended Quater September 2025Nov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2025
Nov 06, 2025Board Meeting Outcome for OutcomeNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 30, 2025
Oct 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementOct 29, 2025
Oct 29, 2025Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter & Half Year Ended 30Th September 2025.Oct 27, 2025
Oct 27, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 57.58
ATR(14)
Less Volatile 66.75
STOCH(9,6)
Neutral 77.63
STOCH RSI(14)
Overbought 93.47
MACD(12,26)
Bullish 18.38
ADX(14)
Weak Trend 22.73
UO(9)
Bearish 52.04
ROC(12)
Uptrend And Accelerating 5.94
WillR(14)
Neutral -22.09
About GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals Limited is an Indian subsidiary of UK-based GSK Plc, engaged in manufacturing, distributing, and trading pharmaceuticals. The company operates in three main product areas: vaccines, specialty medicines, and general medicines. It has manufacturing facilities in Nashik and Thane, with a clinical development center in Bangalore. The company's portfolio...more
Website
Chairperson NameRenu S Karnad
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
